Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
ReViral Ltd
1696
ReViral Ltd
Technology
Biotechnology
Health Care
Medical
Therapeutics
ReViral is a UKbased biotechnology company developing firstinclass drugs to treat RSV infections.
Suggest edits
Type
B2c
Founded
2011
Raised
$99M
Follow us
Also headquartered in London
Blockchain
Reuters
Springwise
BBC
Revolut
Volkswagen
DeepMind
HSBC
Cambridge Analytica
Ubuntu
Companies in the same industry
LifeMine Therapeutics
Grid Therapeutics
Ribon Therapeutics
Dyne Therapeutics
IMPACT Therapeutics
Betalin Therapeutics Inc
Fountain Therapeutics
Asher Bio
Egle Therapeutics
Biomoti
Alexa global traffic share
Twitter followers
Overview
Funding
2
Add info
Latest funding
$44,000,000
Venture capital (Series C) - 2020
New Leaf Venture Partners
Perceptive Advisors
OrbiMed Advisors
+5
$55,000,000
Venture capital (Series B) - 2018
New Leaf Venture Partners
Perceptive Advisors
OrbiMed
+3
Team Size
1–10
Employees
I work here
Location
London
,
United Kingdom
Headquarters
Explore London
Pulse 2.0
,
MedCity News
Why Pfizer (PFE) Is Buying ReViral For Up To $525 Million
$44,000,000
Venture capital (Series C)
FinSMEs
ReViral Raises $44M in Series C Financing
PE HUB
VC-backed ReViral taps Musso as CFO
$55,000,000
Venture capital (Series B)
MedCity News
,
FinSMEs
,
PE HUB
ReViral closes $55 million Series B funding round for RSV drug
